Citadel Advisors
RCKT icon

Citadel Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Citadel Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-67,300
Closed -$241K – 14646
2026
Q1 		$241K Buy
67,300
+38,700
+135% +$154K ﹤0.01% 10990
2025
Q4 		$100K Sell
28,600
-50,100
-64% -$172K ﹤0.01% 11639
2025
Q3 		$257K Sell
78,700
-26,300
-25% -$82.8K ﹤0.01% 10708
2025
Q2 		$257K Buy
105,000
+37,300
+55% +$189K ﹤0.01% 10145
2025
Q1 		$452K Sell
67,700
-600
-0.9% -$5.93K ﹤0.01% 8699
2024
Q4 		$859K Buy
68,300
+49,700
+267% +$748K ﹤0.01% 7373
2024
Q3 		$344K Sell
18,600
-7,300
-28% -$150K ﹤0.01% 9044
2024
Q2 		$558K Buy
25,900
+13,200
+104% +$303K ﹤0.01% 7835
2024
Q1 		$342K Sell
12,700
-11,400
-47% -$324K ﹤0.01% 9193
2023
Q4 		$722K Buy
24,100
+3,900
+19% +$86.1K ﹤0.01% 7324
2023
Q3 		$414K Buy
20,200
+14,200
+237% +$258K ﹤0.01% 8488
2023
Q2 		$119K Sell
6,000
-4,700
-44% -$95K ﹤0.01% 10667
2023
Q1 		$183K Sell
10,700
-7,300
-41% -$143K ﹤0.01% 10326
2022
Q4 		$352K Buy
+18,000
New +$331K ﹤0.01% 8969
2021
Q3 		– Sell
-71,500
Closed -$3.17M – 14499
2021
Q2 		$3.17M Sell
71,500
-2,600
-4% -$113K ﹤0.01% 5465
2021
Q1 		$3.29M Sell
74,100
-500
-0.7% -$27.5K ﹤0.01% 5221
2020
Q4 		$4.09M Buy
+74,600
New +$2.72M ﹤0.01% 4015
2020
Q2 		– Sell
-19,800
Closed -$276K – 10376
2020
Q1 		$276K Buy
+19,800
New +$392K ﹤0.01% 7483
2019
Q2 		– Sell
-13,800
Closed -$242K – 9731
2019
Q1 		$242K Buy
13,800
+2,400
+21% +$37.9K ﹤0.01% 7922
2018
Q4 		$169K Sell
11,400
-1,700
-13% -$28.2K ﹤0.01% 7986
2018
Q3 		$323K Buy
+13,100
New +$284K ﹤0.01% 7446
2017
Q3 		– Sell
-4,175
Closed -$32K – 7942
2017
Q2 		$32K Sell
4,175
-1,500
-26% -$11.2K ﹤0.01% 7193
2017
Q1 		$45K Sell
5,675
-725
-11% -$4.88K ﹤0.01% 7065
2016
Q4 		$156K Buy
+6,400
New +$183K ﹤0.01% 6484

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Citadel Advisors's RCKT Position: Q2 2026 in Review

Citadel Advisors opened a new position in Rocket Pharmaceuticals (RCKT) in Q2 2026: 71,170 shares worth $243K. The stake represents ﹤0.01% of the portfolio and ranks #11602 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in RCKT as recently as Q4 2025.

Citadel Advisors first reported a position in RCKT in Q3 2015 and has held it in 40 quarters since. The position peaked at $73.7M in Q4 2023. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Citadel Advisors held 71,170 shares of Rocket Pharmaceuticals worth $243K as of Q2 2026.
  • Rocket Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11602 holding.
  • Citadel Advisors first reported a position in Rocket Pharmaceuticals in Q3 2015 and has held it in 40 quarters since.
  • Citadel Advisors's Rocket Pharmaceuticals position peaked at $73.7M in Q4 2023.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.